Vaccine for HPV-positive head and neck cancer
Treatments studied
Part of Cancer, Infections clinical trials.
This trial tests an investigational vaccine called BVAC-E6E7 for head and neck cancer caused by HPV types 16 or 18 that has come back or spread. It is for people who have already tried standard treatments like platinum chemo or immunotherapy, or can't take them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older and have given consent to provide blood and tissue samples.
- Your head and neck cancer is HPV type 16 or 18 positive (confirmed by biopsy or a stored tissue sample).
- Your cancer has spread or come back (recurrent/metastatic) and you have either tried platinum chemotherapy or cannot take it for medical reasons, or the cancer got worse within 6 months of finishing immunotherapy.
- You can still do most of your daily activities (ECOG score 0 or 1) and are expected to live at least 3 more months.
- You do not have other uncontrolled cancers, serious heart problems, active autoimmune diseases, or HIV/hepatitis B or C.
- Your blood counts and kidney/liver function are within certain limits, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new nasal vaccine combined with an immunotherapy drug (tislelizumab) given before surgery for people with HPV-positive oropharyngeal cancer. The goal is to help the immune system fight the cancer and potentially improve outcomes after surgery.
This Phase 2 trial tests an immune-cell treatment (E7 TCR T cells) designed to attack cancers caused by HPV type 16. It may help people whose HPV-16+ cancer has come back or not responded to standard treatment.
This trial is testing a combination of two investigational drugs (VB10 and pembrolizumab) in patients with a specific type of head and neck cancer that has returned or spread. The goal is to see if this treatment is safe and effective.
This study tests a new combination of drugs and a vaccine before standard radiation for HPV-positive throat cancer. It aims to use a less intense radiation dose, which may reduce side effects while still being effective.
This Phase 1/2 trial tests a one-time infusion of special immune T cells made to recognize your HPV16 tumor. It may help your body attack the cancer, while researchers closely monitor safety and early effectiveness.
This Phase 2 study tests a “risk-adapted” treatment plan for HPV-related throat cancer, using an HPV DNA blood test to help decide how treatment is done. If your baseline blood test shows detectable HPV DNA, the study may help tailor therapy to your risk and potentially improve outcomes while limiting unnecessary treatment.
Hear when a new HPV (Human Papillomavirus)-Associated Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.